Please login to the form below

Not currently logged in
Email:
Password:

GSK commits to fight HIV/AIDS in Africa

GSK has announced new initiatives to improve research, development and access to HIV/AIDS medicines for children in Sub-Saharan Africa

GlaxoSmithKline (GSK) has announced new initiatives to improve research, development and access to HIV/AIDS medicines for children in Sub-Saharan Africa.

The pharmaceutical company will create a new 'Positive Action for Children Fund', providing £50m over 10 years. A further £10m will be invested in research and development of new HIV/AIDS medicines for children through a Public Private Partnership.

In addition to this funding, GSK has made a voluntary licence agreement with South African Aspen Pharmacare to develop a cheaper generic version of Ziagen (abacavir) – GSK's HIV/AIDS treatment. The company is also investigating the feasibility of collaborations with other manufacturers to develop new combination treatments.

Speaking at the Zingatia Maisha HIV programme in Kenya, Andrew Witty, CEO of GSK, said that the treatment of children with HIV/AIDS remains a significant unmet medical need and that we must do a better job at preventing HIV in children.

"Our objective for Africa is clear - to make existing medicines as widely available as possible while at the same time ensuring sustained investment into R&D for a new generation of medicines," Witty said.

As part of their commitment to improving global health, GSK has a policy of providing HIV medicines to countries most in need on a not-for-profit basis. GSK has eight licensing agreements covering anti-retrovirals in Africa. Under these terms, 279 million generic Epivir (lamivudine) and Combivir (Zidovudine + Lamivudine) tablets were supplied to Africa in 2008.

In April, GSK and Pfizer announced the formation of a new company focusing on research, development and commercialisation of HIV medicines. The commitment of the new company to fighting HIV/AIDS in the world's poorest countries is reiterated in this latest announcement.

15th July 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics